Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus TENOFOVIR ALAFENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus TENOFOVIR ALAFENAMIDE.
EMTRICITABINE vs TENOFOVIR ALAFENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor that, after intracellular conversion to tenofovir diphosphate, inhibits HIV-1 and HBV reverse transcriptase by competing with the natural substrate deoxyadenosine 5'-triphosphate and by DNA chain termination after incorporation into viral DNA.
200 mg orally once daily, typically in combination with other antiretroviral agents.
25 mg orally once daily with food for HIV-1 infection; 25 mg orally once daily for chronic hepatitis B.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 0.51 hours for tenofovir alafenamide, but active metabolite tenofovir diphosphate has intracellular half-life ~150–180 hours in PBMCs, supporting once-daily dosing.
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Renal elimination: ~70% unchanged via glomerular filtration and active tubular secretion; fecal: 2–5%; biliary: <1%.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."